Immunovant, INC. 8-K Filing
Ticker: IMVT · Form: 8-K · Filed: Dec 12, 2025 · CIK: 1764013
Sentiment: neutral
Filing Stats: 537 words · 2 min read · ~2 pages · Grade level 10.2 · Accepted 2025-12-12 16:15:25
Key Financial Figures
- $0.0001 — ange on which registered Common Stock, $0.0001 par value per share IMVT The Nasdaq
- $21.00 — Common Stock"), at an offering price of $21.00 per share. Roivant Sciences Ltd., the C
- $550 million — er offering expenses were approximately $550 million. The offering was made pursuant to an
Filing Documents
- d68980d8k.htm (8-K) — 25KB
- d68980dex11.htm (EX-1.1) — 206KB
- d68980dex51.htm (EX-5.1) — 9KB
- g68980dsp00.jpg (GRAPHIC) — 4KB
- 0001193125-25-317577.txt ( ) — 412KB
- imvt-20251210.xsd (EX-101.SCH) — 3KB
- imvt-20251210_lab.xml (EX-101.LAB) — 17KB
- imvt-20251210_pre.xml (EX-101.PRE) — 11KB
- d68980d8k_htm.xml (XML) — 3KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description of Exhibit 1.1* Underwriting Agreement, between the Company and Leerink Partners LLC, dated as of December 10, 2025. 5.1 Opinion of Sidley Austin LLP. 23.1 Consent of Sidley Austin LLP (included with the opinion filed as Exhibit 5.1). 104 Cover Page Interactive Data File (embedded with Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. IMMUNOVANT, INC. By: /s/ Tiago Giro Name: Tiago Giro Title: Chief Financial Officer Dated: December 12, 2025